Hispolon (HISP) is a bioactive compound isolated from Phellinu linteus. It has various pharmacological activities, including antioxidant, anti-inflammatory, and anti-cancer. However, its anti-osteoclastogenic activity has not yet been reported. Hence, in the current study, we have explored the anti-osteoclastogenic activity of HISP and elucidated the molecular mechanisms. HISP inhibited the RANKL induced differentiation of RAW 264.7 cells into osteoclasts in a dose-dependent manner. Mechanistic studies showed that HISP inhibited RANKL-mediated activation of NF-κB and MAPK signaling pathways in osteoclast precursors RAW 264.7 cells. In addition, Hispolon also downregulated the expression of master transcriptional factors essential for osteoclast differentiation, such as NFATc1 and c-FOS. In conclusion, these findings establish molecular mechanisms behind the anti-osteoclastogenic activity of HISP.

Hispolon (HISP) 是一种从桑黄中分离出来的生物活性化合物. 它具有多种药理活性，包括抗氧化、抗炎和抗癌。然而，其抗破骨细胞活性尚未见报道。因此，在目前的研究中，我们探索了 HISP 的抗破骨细胞活性并阐明了分子机制。HISP 以剂量依赖性方式抑制 RANKL 诱导的 RAW 264.7 细胞分化为破骨细胞。机制研究表明，HISP 抑制 RANKL 介导的破骨细胞前体 RAW 264.7 细胞中 NF-κB 和 MAPK 信号通路的激活。此外，Hisplon 还下调了破骨细胞分化所必需的主要转录因子的表达，例如 NFATc1 和 c-FOS。总之，这些发现建立了 HISP 抗破骨细胞活性背后的分子机制。